AU2003282722A8 - Therapeutic compositions - Google Patents

Therapeutic compositions

Info

Publication number
AU2003282722A8
AU2003282722A8 AU2003282722A AU2003282722A AU2003282722A8 AU 2003282722 A8 AU2003282722 A8 AU 2003282722A8 AU 2003282722 A AU2003282722 A AU 2003282722A AU 2003282722 A AU2003282722 A AU 2003282722A AU 2003282722 A8 AU2003282722 A8 AU 2003282722A8
Authority
AU
Australia
Prior art keywords
therapeutic compositions
therapeutic
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003282722A
Other versions
AU2003282722A1 (en
Inventor
David Bumcrot
Nagesh Mahanthappa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alnylam Pharmaceuticals Inc
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of AU2003282722A8 publication Critical patent/AU2003282722A8/en
Publication of AU2003282722A1 publication Critical patent/AU2003282722A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003282722A 2002-10-02 2003-10-02 Therapeutic compositions Abandoned AU2003282722A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41569802P 2002-10-02 2002-10-02
US60/415,698 2002-10-02
PCT/US2003/031717 WO2004030634A2 (en) 2002-10-02 2003-10-02 Therapeutic compositions

Publications (2)

Publication Number Publication Date
AU2003282722A8 true AU2003282722A8 (en) 2004-04-23
AU2003282722A1 AU2003282722A1 (en) 2004-04-23

Family

ID=32069900

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003282722A Abandoned AU2003282722A1 (en) 2002-10-02 2003-10-02 Therapeutic compositions

Country Status (2)

Country Link
AU (1) AU2003282722A1 (en)
WO (1) WO2004030634A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005003788A1 (en) * 2005-01-19 2006-07-20 Eberhard-Karls-Universität Tübingen Universitätsklinikum siRNA molecules for the treatment of blood vessels
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
KR101141544B1 (en) 2009-03-13 2012-05-03 한국과학기술원 Multi-conjugate of siRNA and preparing method thereof
CA2764158A1 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
KR20180039621A (en) 2015-06-15 2018-04-18 엠펙 엘에이, 엘엘씨 The defined multijunctional oligonucleotides
CN108366966A (en) 2015-08-24 2018-08-03 光环生物干扰疗法公司 Polynucleotides nano particle and application thereof for adjusting gene expression
KR102623311B1 (en) 2017-02-06 2024-01-10 엠펙 엘에이, 엘.엘.씨. Multiconjugate oligonucleotides with reduced renal clearance
AU2022366987A1 (en) 2021-10-14 2024-05-16 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
TW202417626A (en) 2022-09-13 2024-05-01 美商亞森諾生物科學公司 Immune cells having co-expressed tgfbr shrnas
WO2024059824A2 (en) 2022-09-16 2024-03-21 Arsenal Biosciences, Inc. Immune cells with combination gene perturbations
WO2024186656A1 (en) 2023-03-03 2024-09-12 Arsenal Biosciences, Inc. Systems targeting psma and ca9

Also Published As

Publication number Publication date
WO2004030634A2 (en) 2004-04-15
WO2004030634A3 (en) 2004-09-23
AU2003282722A1 (en) 2004-04-23

Similar Documents

Publication Publication Date Title
GB2389530B (en) Pharmaceutical compositions
EP1603543A4 (en) Therapeutic compositions
GB0212062D0 (en) Jetable compositions
IL165372A0 (en) Immunodenic compositions
GB0224415D0 (en) Compositions
GB2391473B (en) Pharmaceutical compositions
EP1556023A4 (en) Nutritional or therapeutic compositions
EP1608385A4 (en) Therapeutic compositions
AU2003279911A8 (en) Therapeutic formulations
GB0208609D0 (en) Compositions
GB2392618B (en) Compositions for therapeutic use
GB0229258D0 (en) Medicinal compositions
GB0222945D0 (en) Therapeutic compositions
GB0221894D0 (en) Compositions
AU2003282722A8 (en) Therapeutic compositions
AU2003269904A8 (en) Antigen-polymer compositions
AU2002365093A8 (en) Therapeutic compositions
AU2003215150A8 (en) Therapeutic compounds
GB0203395D0 (en) Compositions
GB0213481D0 (en) Pharmaceutical compositions
HK1081451A1 (en) Medicinal composition
GB0203396D0 (en) Compositions
GB0109428D0 (en) Therapeutic compositions
GB0217366D0 (en) Compositions
HK1062274A1 (en) Medicinal composition

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase